Keap1在肾细胞癌中的表达及其作用
Expression and role of Keap1 in renal cell carcinoma

DOI: 10.6040/j.issn.1671-7554.0.2016.162

Keywords: 肾细胞癌,细胞增殖,核因子E2相关因子2,Kelch样ECH相关蛋白-1,
Renal carcinoma,Kelch-like ECH-associated protein1,Proliferation,Nuclear factor E2-related factor 2

Full-Text   Cite this paper   Add to My Lib

Abstract:

References

[1]	Brookman-May SD, May M, Shariat SF, et al. Time to recurrence is a significant predictor of cancer-specific survival after recurrence in patients with recurrent renal cell carcinoma-results from a comprehensive multi-centre database(CORONA/SATURN-Project)[J]. BJU Int, 2013, 112(7): 909-916.
[2]	Leinonen HM, Kansanen E, Polonen P, et al. Role of the Keap1-Nrf2 pathway in cancer[J]. Adv Cancer Res, 2014, 122: 281-320. doi: 10.1016/B978-0-12-420117-0.00008-6.
[3]	Kobayashi A, Kang MI, Okawa H, et al. Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2[J]. Mol Cell Biol, 2004, 24(16): 7130-7139.
[4]	Guo Y, Yu S, Zhang C, et al. Epigenetic regulation of Keap1-Nrf2 signaling[J]. Free RadicBiol Med, 2015, 88(Pt B): 337-349.
[5]	Rushmore TH, Morton MR, Pickett CB. The antioxidant responsive element. Activation by oxidative stress and identification of the DNA consensus sequence required for functional activity[J]. J Biol Chem, 1991, 266(18): 11632-11639.
[6]	Tian H, Zhang B, Di J, et al. Keap1: One stone kills three birds Nrf2, IKKβ and Bcl-2/Bcl-xL[J]. Cancer Letters, 2012, 325(1): 26-34.
[7]	Zhao CR, Gao ZH, Qu XJ. Nrf2-ARE signaling pathway and natural products for cancer chemoprevention[J]. Cancer Epidemiol, 2010, 34(5): 523-533.
[8]	张凯茹, 闫惠琴, 王燕, 等. Nrf2及其靶基因在人肺腺癌A549顺铂耐药细胞株中的表达和意义[J]. 中国肺癌杂志, 2009, 12(11): 1150-1154. ZHANG Kairu, YAN Huiqin, WANG Yan, et al. Expression and significance of Nrf2 and its target genes in pulmonary adenocarcinoma A549 cells resistant to cisplatin[J]. Chinese Journal of Lung Cancer, 2009, 12(11): 1150-1154.
[9]	Ohta T, Iijima K, Miyamoto M, et al. Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth[J]. Cancer Res, 2008, 68(5): 1303-1309.
[10]	Leinonen HM, Kansanen E, Polonen P, et al. Dysregulation of the Keap1-Nrf2 pathway in cancer[J]. Biochem Soc Trans, 2015, 43(4): 645-649.
[11]	Huang Y, Li W, Su ZY, et al. The complexity of the Nrf2 pathway: beyond the antioxidant response[J]. J Nutr Biochem, 2015, 26(12): 1401-1413.
[12]	OConnell MA, Hayes JD. The Keap1/Nrf2 pathway in health and disease: from the bench to the clinic[J]. Biochem Soc Trans, 2015, 43(4): 687-689.
[13]	Wang R, An J, Ji F, et al. Hypermethylation of the Keap1 gene in human lung cancer cell lines and lung cancer tissues[J]. Biochem Biophys Res Commun, 2008, 373(1): 151-154.
[14]	曹宝山, 朱翔, 陈森, 等. Keap1在非小细胞肺癌中的表达及与化疗疗效相关性的研究[J]. 中国肺癌杂志, 2012, 15(10): 591-596. CAO Baoshan, ZHU Xiang, CHEN Sen, et al. Keap1 expression for predicting the chemoresistance and prognosis of advanced non-small cell lung cancer[J]. Chinese Journal of Lung Cancer, 2012, 15(10): 591-596.
[15]	Shim GS, Manandhar S, Shin DH, et al. Acquisition of doxorubicin resistance in ovarian carcinoma cells accompanies activation of the NRF2 pathway[J]. Free RadicBiol Med, 2009, 47(11): 1619-1631.
[16]	Huang CF, Zhang L, Ma SR, et al. Clinical significance of Keap1 and Nrf2 in oral squamous cell carcinoma[J]. PLoS One, 2013, 8(12): e83479. doi: 10.1371/journal.pone.0083479. eCollection 2013.
[17]	Padmanabhan B, Tong KI, Ohta T, et al. Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer[J]. Mol Cell, 2006, 21(5): 689-700.

Full-Text